Decision relating to the listing of diltiazem hydrochloride (Apo-Diltiazem)
PHARMAC is pleased to announce the approval of an agreement with Apotex NZ Limited relating to the supply of diltiazem hydrochloride CD (Apo-Diltiazem CD) for the treatment of hypertension, angina, and certain heart rhythm disorders.
This decision results in:
- long-acting diltiazem hydrochloride (Apo-Diltiazem CD) remaining listed;
- subsidy and delisting protection for Apo-Diltiazem CD until 30 June 2018; and
- the price and subsidy of Apo-Diltiazem CD in Section B (Community) and Section H (Hospital) of the Pharmaceutical Schedule remaining the same, as follows:
|Chemical||Form and strength||Brand||Pack size||Price and subsidy
(ex-man., ex. GST)
|Diltiazem hydrochloride||120 mg long acting Cap||Apo-Diltiazem CD||500||$31.83|
|Diltiazem hydrochloride||180 mg long acting Cap||Apo-Diltiazem CD||500||$47.67|
|Diltiazem hydrochloride||240 mg long acting Cap||Apo-Diltiazem CD||500||$63.58|
We appreciate the feedback that we received and acknowledge the time people took to respond. All consultation responses received by 21 April 2015 were considered in their entirety in making a decision on the proposed changes.
All responses were supportive of the proposal, and no issues were raised in relation to specific aspects of the proposal.
If you have any questions about this decision, you can email us at firstname.lastname@example.org or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.